Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2026)

Zevra Therapeutics has reported Gross Profit for 7 years, with the latest figure at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 80.01% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $105.3 million (up 229.81% YoY), and the FY2025 full-year result was $90.0 million, up 455.65% from the prior year.
• Gross Profit for Q1 2026 stood at $34.3 million, up from $32.6 million in the prior quarter.
• The five-year high for Gross Profit was $34.3 million in Q1 2026, with the low at $28000.0 in Q2 2022.
• Historically, Gross Profit has averaged $10.3 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2022 — Gross Profit slumped 99.75% — and 2023, when it jumped 27732.14%.
• Zevra Therapeutics' Gross Profit stood at $2.2 million in 2022, then jumped by 438.6% to $11.7 million in 2023, then decreased by 8.95% to $10.6 million in 2024, then surged by 206.69% to $32.6 million in 2025, then increased by 5.06% to $34.3 million in 2026.
• The last three Gross Profit figures came in at $34.3 million (Q1 2026), $32.6 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.